Relmada Therapeutics Valuation
| RLMD Stock | USD 3.72 0.18 4.62% |
At this time, the company appears to be undervalued. Relmada Therapeutics holds a recent Real Value of $4.41 per share. The prevailing price of the company is $3.72. Our model determines the value of Relmada Therapeutics from analyzing the company fundamentals such as Shares Owned By Institutions of 18.88 %, shares outstanding of 73.33 M, and Return On Equity of -1.97 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Relmada Therapeutics' valuation include:
Undervalued
Today
Please note that Relmada Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Relmada Therapeutics is based on 3 months time horizon. Increasing Relmada Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Relmada stock is determined by what a typical buyer is willing to pay for full or partial control of Relmada Therapeutics. Since Relmada Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Relmada Stock. However, Relmada Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.72 | Real 4.41 | Target 5.5 | Hype 3.71 |
The real value of Relmada Stock, also known as its intrinsic value, is the underlying worth of Relmada Therapeutics Company, which is reflected in its stock price. It is based on Relmada Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Relmada Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Relmada Therapeutics helps investors to forecast how Relmada stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Relmada Therapeutics more accurately as focusing exclusively on Relmada Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Relmada Therapeutics' intrinsic value based on its ongoing forecasts of Relmada Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Relmada Therapeutics' closest peers. If more than one evaluation category is relevant for Relmada Therapeutics we suggest using both methods to arrive at a better estimate.
Relmada Therapeutics Cash |
|
Relmada Therapeutics Total Value Analysis
Relmada Therapeutics is at this time expected to have valuation of 258.91 M with market capitalization of 330.73 M, debt of 10.3 M, and cash on hands of 211.96 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Relmada Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
258.91 M | 330.73 M | 10.3 M | 211.96 M |
Relmada Therapeutics Asset Utilization
One of the ways to look at asset utilization of Relmada is to check how much profit was generated for every dollar of assets it reports. Relmada Therapeutics holds a negative application of assets of -1.02 pct., losing $0.0102 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Relmada Therapeutics shows how discouraging it operates for each dollar spent on its assets.Relmada Therapeutics Profitability Analysis
Based on Relmada Therapeutics' profitability indicators, Relmada Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Relmada Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2011-12-31 | Previous Quarter -9.9 M | Current Value -10.1 M | Quarterly Volatility 13.7 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.26 | 0.31 |
|
|
For Relmada Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Relmada Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Relmada Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Relmada Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Relmada Therapeutics over time as well as its relative position and ranking within its peers.
Relmada Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Relmada Therapeutics is estimated to be -0.09 with future projections ranging from a low of -0.09 to a high of -0.09. Relmada Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.78. Please be aware that the consensus of earnings estimates for Relmada Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Relmada Therapeutics Earnings Estimation Breakdown
The calculation of Relmada Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Relmada Therapeutics is estimated to be -0.09 with the future projection ranging from a low of -0.09 to a high of -0.09. Please be aware that this consensus of annual earnings estimates for Relmada Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.09 Lowest | Expected EPS | -0.09 Highest |
Relmada Therapeutics Earnings Projection Consensus
Suppose the current estimates of Relmada Therapeutics' value are higher than the current market price of the Relmada Therapeutics stock. In this case, investors may conclude that Relmada Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Relmada Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 3 | 50.0% | 0.0 | -0.09 | -1.78 |
Relmada Therapeutics Ownership Allocation
Relmada Therapeutics owns a total of 73.33 Million outstanding shares. Relmada Therapeutics holds 10.75 pct. of its outstanding shares held by insiders and 18.88 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Relmada Therapeutics Profitability Analysis
Net Loss for the year was (79.98 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Relmada Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Relmada Therapeutics and how it compares across the competition.
About Relmada Therapeutics Valuation
The stock valuation mechanism determines Relmada Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Relmada Therapeutics. We calculate exposure to Relmada Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Relmada Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.4 K | -1.5 K | |
| Pretax Profit Margin | (1.75) | (1.83) | |
| Operating Profit Margin | (1.75) | (1.83) | |
| Net Loss | (1.75) | (1.83) | |
| Gross Profit Margin | 0.31 | 0.26 |
Relmada Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Relmada Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Relmada we look at many different elements of the entity such as Relmada's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Relmada Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Relmada Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Relmada Therapeutics' worth.Complementary Tools for Relmada Stock analysis
When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |